Alexandria Real Estate Posts $73.7M Q2 Loss as Life Sciences Real Estate Slump Deepens

Alexandria Real Estate Equities (搜索)搜索该公司 posted a $73.7 million loss in the second quarter of 2025, underscoring the deepening downturn in the life sciences real estate market as the sector continues to grapple with a prolonged supply glut that has pushed vacancy rates to multi-year highs and eroded rental income.

The real estate investment trust, which specializes in owning and operating laboratory and office campuses for biotechnology and pharmaceutical tenants across key innovation clusters including greater Boston, the San Francisco Bay Area, and San Diego, saw net operating income drop 10% compared to the prior period. The results highlight a market that has struggled to regain momentum since the pandemic-era peak, with lab rents declining 5.3% year-over-year to $64 per square foot and overall vacancy climbing to 24.3%, according to Cushman & Wakefield's Q2 life sciences report.

"The industry has decoupled from demand on the ground," Alexandria Chairman Joel Marcus said on the company's earnings call, capturing the disconnect between broader life sciences sector improvements and the leasing reality facing landlords.

Occupancy and Leasing Under Pressure

Alexandria's occupancy rate fell to 86.9% in the second quarter, a marked decline from 91.7% in the first quarter of 2025, directly impacting net operating income. Rental rates dropped 0.7%, a more moderate decline than the 15% decrease posted in the first quarter, but still not a reversal into growth territory.

The company's Q2 leasing volume surpassed 1 million square feet, beating the average of recent quarters and jumping 60% from the prior quarter's sluggish performance. However, the composition of tenants signing these leases reveals a fundamental shift in the market. Only 6% of new tenants were public biotech companies—a modest improvement from the previous quarter when none signed new deals, but still indicative of persistent fundraising challenges in the sector.

"Public biotech right now is slow and lagging," said Alexandria Executive Vice President Hallie Kuhn.

Roughly 40% of leasing activity came from medical product and device firms, described by Alexandria Chief Financial Officer Marc Binda as the "picks and shovels" of the biotech world. Another 30% originated from advanced tech tenants, with significant leases signed at Greater Boston properties including 3000 Minuteman Road and 311 Arsenal Street. Binda indicated that tech tenants are expected to constitute a significant portion of leasing in the coming quarter as well.

Impairment Charges and Disposition Challenges

Alexandria took a $222 million impairment charge related to property sales, reflecting a weak market for properties and land that were previously highly valued as ground-up development or conversion opportunities. This included a $64.2 million impairment tied to a land parcel in San Diego's Sorrento Mesa submarket, illustrating the difficulties even within core life sciences markets.

Binda cautioned that additional impairments may materialize in upcoming quarters.

Property sales through early August totaled $170 million, a muted figure relative to the company's $2.9 billion disposition target for the year. CEO Peter Moglia noted that financing is taking longer for buyers to secure, pushing back timelines for many potential sales. Still, Binda pointed to $1.2 billion in deals that remain "in progress," and Chairman Marcus downplayed concerns about "artificial timing," expressing confidence that the company would meet its disposition targets.

Upcoming Vacancies and Strategic Adjustments

The company faces 451,000 square feet of lease expirations in the second half of 2025 and an additional 1.4 million square feet expiring next year, with anticipated downtime of 12 to 24 months between tenants. Binda emphasized that future performance will hinge in part on Alexandria's ability to quickly fill those gaps.

"We are laser-focused on leasing up vacant space," he said.

Alexandria has also been evaluating its construction pipeline, which has been reduced by one-fifth since the start of the year, with 1.4 million square feet of projects under review for potential pivoting to further reduce construction funding requirements.

On a more positive note, concessions showed improvement, with the average amount of free rent in Alexandria leases dropping from two months per year to 1.5 months. The company also noted a slight uptick in leases in the 20,000-to-100,000-square-foot range, a category that has lagged in recent quarters.

Outlook and Market Context

Despite the challenging quarter, Binda projected that occupancy would stabilize around 87% by year-end, with an estimated 950,000 square feet of leasing anticipated in the third quarter. This steady rate of activity is expected to contribute to stronger net operating income performance in the second half of 2026.

Marcus briefly addressed regulatory headwinds, suggesting that "truly knowledgeable and expert leadership" at the National Institutes of Health, Food and Drug Administration, and Department of Health and Human Services would "certainly go a long way," though he devoted less time to federal agency issues than on prior earnings calls.

Since the earnings release, Alexandria stock has dropped roughly 4% to just under $49 per share, though it remains above the $40 year-to-date low reached in April. The company's performance continues to reflect the interplay between structural demand drivers for life sciences space and the cyclical forces shaping near-term leasing activity and asset valuations.